CNS vasculitis in a patient with MS on daclizumab monotherapy

Neurology

Volumn 80, Issue 5, 2013, Pages 453-457

  Ohayon, Joan ^a   Oh, Unsong ^b   Richert, Nancy ^c   Martin, Jayne ^d   Vortmeyer, Alexander ^e   McFarland, Henry ^a   Bielekova, Bibiana ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c BIOGEN   (United States)

^d Columbia University ^*  (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD56 ANTIGEN; CXCL13 CHEMOKINE; CYCLOPHOSPHAMIDE; DACLIZUMAB; GAMMA INTERFERON; INTERLEUKIN 12P40; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; METHYLPREDNISOLONE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ARTHRALGIA; ARTICLE; BRAIN VASCULITIS; CASE REPORT; CELL EXPANSION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FEVER; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; KILLER CELL; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OFF LABEL DRUG USE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEOCYTOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SMALL VESSEL VASCULITIS; STEREOTACTIC BIOPSY; SYMPTOM; TREATMENT RESPONSE; WEIGHT REDUCTION; WHITE MATTER;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD56; CYCLOPHOSPHAMIDE; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KILLER CELLS, NATURAL; MAGNETIC RESONANCE IMAGING; MALE; METHYLPREDNISOLONE; MULTIPLE SCLEROSIS; VASCULITIS, CENTRAL NERVOUS SYSTEM;

EID: 84873661188     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31827f0f42     Document Type: Article

References (10)

1. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon-beta. Proc Natl Acad Sci USA 2004;101:8705-8708. (Pubitemid 38745835)
2. Bielekova B, Richert N, Herman ML, et al. Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology 2011;77:1877-1886.
3. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009;66:483-489.
4. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-789. (Pubitemid 47300936)
5. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56:864-867. (Pubitemid 39578450)
6. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010;9:381-390.
7. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R-alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006;103:5941-5946.
8. Oh U, Blevins G, Griffith C, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009;66:471-479.
9. Wuest SC, Edwan JH, Martin JF, et al. A role for inter-leukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011;17:604-609.
10. Martin JF, Perry JS, Jakhete NR, Wang X, Bielekova B. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells. J Immunol 2010;185:1311-1320.